Integer Holdings Co. (NYSE:ITGR) Receives $137.29 Consensus Price Target from Brokerages

Integer Holdings Co. (NYSE:ITGR) has been assigned an average rating of “Moderate Buy” from the seven brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $138.71.

ITGR has been the topic of a number of research reports. Benchmark reiterated a “buy” rating and set a $130.00 target price on shares of Integer in a research report on Wednesday, October 2nd. Bank of America increased their price objective on Integer from $135.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, October 1st. KeyCorp boosted their target price on Integer from $139.00 to $144.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 15th. Oppenheimer initiated coverage on Integer in a report on Tuesday, July 16th. They issued an “outperform” rating and a $135.00 price target on the stock. Finally, Truist Financial boosted their price objective on Integer from $145.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, October 14th.

Integer Stock Up 0.0 %

NYSE ITGR opened at $130.43 on Friday. The stock’s 50 day simple moving average is $126.80 and its 200 day simple moving average is $120.63. Integer has a one year low of $69.40 and a one year high of $133.53. The firm has a market cap of $4.37 billion, a PE ratio of 45.13, a price-to-earnings-growth ratio of 1.86 and a beta of 1.08. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.29 and a quick ratio of 1.96.

Integer (NYSE:ITGR) last announced its earnings results on Thursday, July 25th. The medical equipment provider reported $1.30 EPS for the quarter, topping the consensus estimate of $1.24 by $0.06. Integer had a return on equity of 11.48% and a net margin of 6.31%. The company had revenue of $436.20 million for the quarter, compared to analysts’ expectations of $437.00 million. During the same quarter in the prior year, the business earned $1.14 earnings per share. The business’s revenue for the quarter was up 9.0% on a year-over-year basis. As a group, sell-side analysts forecast that Integer will post 5.3 earnings per share for the current fiscal year.

Insider Activity at Integer

In other news, Director Jean M. Hobby sold 11,960 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $119.66, for a total transaction of $1,431,133.60. Following the completion of the transaction, the director now directly owns 2,280 shares in the company, valued at approximately $272,824.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Integer

Institutional investors and hedge funds have recently made changes to their positions in the company. Congress Asset Management Co. MA grew its stake in Integer by 12.5% in the fourth quarter. Congress Asset Management Co. MA now owns 421,524 shares of the medical equipment provider’s stock valued at $41,765,000 after acquiring an additional 46,776 shares during the period. Quadrature Capital Ltd acquired a new position in shares of Integer in the 4th quarter valued at approximately $378,000. HighPoint Advisor Group LLC bought a new stake in Integer during the 4th quarter worth approximately $221,000. Canandaigua National Bank & Trust Co. acquired a new stake in Integer during the 1st quarter worth approximately $233,000. Finally, Guidance Capital Inc. bought a new position in Integer in the first quarter valued at approximately $500,000. Institutional investors and hedge funds own 99.29% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.